Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16965089 | 0.95 | CHRNB2 (0.39) | CHRNB2CHRNA4RAB9ACHRM2CHRM4 | |
| SCHEMBL16965415 | 0.93 | CHRNB2 (0.35) | CHRNB2CHRNA4RAB9ACHRM2CHRM4 | |
| SCHEMBL8471165 | 0.84 | CHRNB2 (0.39) | CHRNB2CHRNA4RAB9ACHRM2CHRM4 | |
| SCHEMBL6897112 | 0.84 | CHRNB2 (0.39) | CHRNB2CHRNA4RAB9ACHRM2CHRM4 | |
| SCHEMBL16964943 | 0.83 | CHRNB2 (0.41) | CHRNB2CHRNA4RAB9ACHRM2CHRM4 | |
| SCHEMBL16965453 | 0.81 | CHRNB2 (0.35) | CHRNB2CHRNA4CHRM2CHRM4CHRM5 | |
| SCHEMBL22267759 | 0.80 | — | — | |
| SCHEMBL6244866 | 0.78 | — | — | |
| SCHEMBL20697362 | 0.77 | CHRNB2 (0.36) | CHRNB2CHRNA4CHRM1CHRM3TSHR | |
| SCHEMBL6894074 | 0.77 | BCHE (0.37) | CHRNB2CHRNA4CHRM2CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230150941-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2023-05-18 | — | — | US | disclosed |
| US-20230150941-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2023-05-18 | — | — | US | disclosed |
| US-11518745-B2 | Heterocyclic compounds for the treatment of neurological and psychological disorders | ALKERMES PHARMA IRELAND LIMITED (IE) | 2022-12-06 | — | — | US | disclosed |
| US-20200407320-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2020-12-31 | — | — | US | disclosed |
| US-10822306-B2 | Heterocyclic compounds for the treatment of neurological and psychological disorders | ALKERMES PHARMA IRELAND LIMITED (IE) | 2020-11-03 | — | — | US | disclosed |
| US-10723728-B2 | Prodrugs of Nh-acidic compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2020-07-28 | — | — | US | disclosed |
| US-20190276406-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2019-09-12 | — | — | US | disclosed |
| US-10040787-B2 | Prodrugs of NH-acidic compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2018-08-07 | — | — | US | disclosed |
| US-10040787-B2 | Prodrugs of NH-acidic compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2018-08-07 | — | — | US | disclosed |
| US-10023537-B2 | Heterocyclic compounds for the treatment of neurological and psychological disorders | ALKERMES PHARMA IRELAND LIMITED (IE) | 2018-07-17 | — | — | US | disclosed |
| US-20110251379-A1 | COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISORDERS | SATORI PHARMACEUTICALS, INC. (US) | 2011-10-13 | — | — | US | disclosed |
| US-20110178068-A1 | Quaternary Ammonium Salt Prodrugs | ALKERMES, INC. (US) | 2011-07-21 | — | — | US | disclosed |
| US-20110178068-A1 | Quaternary Ammonium Salt Prodrugs | ALKERMES, INC. (US) | 2011-07-21 | — | — | US | disclosed |
| US-20110166128-A1 | Diaryldiazepine Prodrugs for the Treatment of Neurological and Psychological Disorders | ALKERMES, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110166194-A1 | Asenapine Prodrugs | ALKERMES, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110166156-A1 | Prodrugs for the Treatment of Schizophrenia and Bipolar Disease | ALKERMES, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110015156-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | ALKERMES, INC. | 2011-01-20 | — | — | US | disclosed |
| US-20110015156-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | ALKERMES, INC. | 2011-01-20 | — | — | US | disclosed |
| US-20110003828-A1 | PRODRUGS OF NH-ACIDIC COMPOUNDS | ALKERMES, INC. | 2011-01-06 | — | — | US | disclosed |
| US-20110003828-A1 | PRODRUGS OF NH-ACIDIC COMPOUNDS | ALKERMES, INC. | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200407320-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | GABBR1, GABBR2, GABRE | CHRNB2 569/4885CHRNA4 233/4885RAB9A 853/4885 |
| US-20110178068-A1 | Quaternary Ammonium Salt Prodrugs | SLC1A5, IDH1, ASS1 | CHRNB2 3204/4885CHRNA4 1789/4885RAB9A 1537/4885 |
| US-10023537-B2 | Heterocyclic compounds for the treatment of neurological and psychological disorders | GABBR1, GABBR2, GABRE | CHRNB2 569/4885CHRNA4 233/4885RAB9A 853/4885 |
| US-10040787-B2 | Prodrugs of NH-acidic compounds | SI, NAAA, NIT2 | CHRNB2 4679/4885CHRNA4 3994/4885RAB9A 1430/4885 |
| US-20110166194-A1 | Asenapine Prodrugs | GRIN1, SCN1B, GRIN2B | CHRNB2 129/4885CHRNA4 9/4885RAB9A 42/4885 |
| US-20110166156-A1 | Prodrugs for the Treatment of Schizophrenia and Bipolar Disease | SLC1A2, BDNF, MAOB | CHRNB2 293/4885CHRNA4 342/4885RAB9A 800/4885 |
| US-20230150941-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | GABBR1, GABBR2, GABRE | CHRNB2 569/4885CHRNA4 233/4885RAB9A 853/4885 |
| US-20110166128-A1 | Diaryldiazepine Prodrugs for the Treatment of Neurological and Psychological Disorders | HTR5A, HTR2C, HTR2B | CHRNB2 749/4885CHRNA4 253/4885RAB9A 2568/4885 |
| US-20110003828-A1 | PRODRUGS OF NH-ACIDIC COMPOUNDS | SI, NAAA, NIT2 | CHRNB2 4679/4885CHRNA4 3994/4885RAB9A 1430/4885 |
| US-10723728-B2 | Prodrugs of Nh-acidic compounds | SI, NAAA, NIT2 | CHRNB2 4679/4885CHRNA4 3994/4885RAB9A 1430/4885 |
| US-11518745-B2 | Heterocyclic compounds for the treatment of neurological and psychological disorders | GABBR1, GABBR2, GABRE | CHRNB2 569/4885CHRNA4 233/4885RAB9A 853/4885 |
| US-20190276406-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | GABBR1, GABBR2, GABRE | CHRNB2 569/4885CHRNA4 233/4885RAB9A 853/4885 |
| US-10822306-B2 | Heterocyclic compounds for the treatment of neurological and psychological disorders | GABBR1, GABBR2, GABRE | CHRNB2 569/4885CHRNA4 233/4885RAB9A 853/4885 |
| US-20110015156-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | GABBR1, GABBR2, GABRE | CHRNB2 569/4885CHRNA4 233/4885RAB9A 853/4885 |
| US-20110251379-A1 | COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISORDERS | CLN6, NLN, ACHE | CHRNB2 102/4885CHRNA4 173/4885RAB9A 1981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.